Skip to main content

News

Press release year list 2024 2023 2022 2021 2020
11/24/2020
Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd
11/16/2020
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
11/10/2020
Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th
11/09/2020
Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update
11/02/2020
Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9
11/02/2020
Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
10/29/2020
Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock
10/28/2020
Forte Biosciences Announces Proposed Public Offering of Common Stock
10/26/2020
  Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis
10/16/2020
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
09/29/2020
Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis
09/09/2020
Forte Biosciences, Inc. Announces Full Publication of Phase 1/2 Data in Science Translational Medicine
08/25/2020
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
08/10/2020
Forte Biosciences, Inc. Announces Second Quarter 2020 Results and Provides General Business Update
08/03/2020
Forte Biosciences, Inc. to Announce Second Quarter 2020 Results on August 10
07/28/2020
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
06/18/2020
Forte Biosciences, Inc. Announces Issuance of New U.S. Patent
06/15/2020
Forte Biosciences, Inc. Announces Closing of Merger With Tocagen